Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
…
32,600€
1,24%
Echtzeit-Aktienkurs Ultragenyx Pharmaceutical
Bid:
Ask:
Nachrichten zur Ultragenyx Pharmaceutical Aktie
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx to Participate in Investor Conferences in December
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
…
Ultragenyx Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
…
Ultragenyx Pharmaceutical Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
…
GNW-Adhoc: Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
^BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.
(NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich…